Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

257.68 -1.25 (-0.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 800,827
Open 259.33
Bid (Size) 257.18 (1)
Ask (Size) 258.68 (1)
Prev. Close 258.93
Today's Range 257.09 - 260.72
52wk Range 194.45 - 319.74
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
California Attorney General Cracks Down On Deceptive Abortion Pill Reversal Claims
California Attorney General Rob Bonta has taken legal action against two anti-abortion organizations, Heartbeat International (HBI) and RealOptions Obria, for making unsupported claims about reversing... 
Via Benzinga
(BIIB) - Analyzing Biogen's Short Interest
Via Benzinga

Performance

YTD
-5.48%
-5.48%
1 Month
-2.69%
-2.69%
3 Month
-9.43%
-9.43%
6 Month
-4.57%
-4.57%
1 Year
+28.44%
+28.44%

More News

Read More
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
Via The Motley Fool
7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth
Via InvestorPlace
Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst
Via Benzinga
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
(BIIB) - Analyzing Biogen's Short Interest
Via Benzinga
Analyst Ratings for Biogen
Via Benzinga
3 Healthcare Stocks to Sell in September Before They Crash & Burn
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For
Via Benzinga
Better Buy: Biogen vs. Eli Lilly
Via The Motley Fool
If You Invested $100 In This Stock 15 Years Ago, You Would Have $500 Today
Via Benzinga
Biogen Appoints Jane Grogan as Head of Research
From Biogen Inc.
Via GlobeNewswire
The 3 Best Biotech Stocks to Buy Now: September 2023
Via InvestorPlace
Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment
Via Investor's Business Daily
The 7 Most Promising Momentum Stocks to Own Now
Via InvestorPlace
The 3 Most Promising Pharma Stocks to Own Now
Via InvestorPlace
Wall Street Thinks This Tiny Biotech Company Could Soar Soon
Via The Motley Fool
Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock
Via InvestorPlace
Is Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fiesta Restaurant Group, Inc. (Nasdaq - FRGI), Veritiv Corporation (NYSE - VRTV), New Relic, Inc. (NYSE - NEWR), Reata Pharmaceuticals, Inc. (Nasdaq - RETA)
From Brodsky & Smith LLC
Via GlobeNewswire
Why Shares of Sage Therapeutics Slumped This Week
Via The Motley Fool
Exposures Product Safety
Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.